Project Grant R01CA296556
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$769K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) worth $718,113 to St. Jude Children's Research Hospital Inc. on January 15, 2025. The grant supports research aimed at understanding the mechanisms by which the MYC oncogenes interact with core regulatory circuitry transcription factors (CRC TFs) and epigenetic modifiers, such as histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), to promote neuroblastoma...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to develop high-quality chemical probes to functionally annotate the epigenetic effector "reader" domains within the Bromodomain PHD Finger Transcription Factor (BPTF) in neuroblastoma, an aggressive pediatric cancer. The $738,024 award, effective from January 1, 2025 to December 31, 2029, aims to optimize BPTF bromodomain and plant homeodomain (PHD)...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
The National Cancer Institute (NCI) awarded a $788,589 Project Grant (CFDA 93.398 Cancer Research Manpower) to Children's Hospital Los Angeles (CHLA) on August 15, 2024. The grant supports research to understand how the transcription factor FOXR2 cooperates with ETS transcription factors to drive the formation of diffuse midline gliomas, a devastating type of childhood brain tumor. The research aims to elucidate the role of MAPK signaling in FOXR2-expressing gliomas and test if ETS transcription...
The National Cancer Institute (NCI) awarded a $531,550 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Texas State University to conduct research on discovering novel druggable targets for neuroblastoma differentiation therapy. The research aims to systematically investigate the human druggable genome to identify differentiation-blocking oncogenes in neuroblastoma cells, validate their functions, and evaluate differentiation-inducing activities of inhibitors...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $172,013 to support the research work of a pediatric oncologist at the University of Colorado-Denver over the period of September 19, 2024 to August 31, 2029. The funded research aims to improve outcomes for children with acute lymphoblastic leukemia, particularly those who experience disease relapse, through the incorporation of novel targeted therapies into treatment regimens. The...
The U.S. National Institute of General Medical Sciences (NIGMS) awarded a $667,480 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to St. Jude Children's Research Hospital Inc. on May 1, 2025. The grant supports a 5-year research project focused on studying the structural and functional dynamics of chromatin, which plays a critical role in cellular processes like gene expression, DNA replication, and cell differentiation. The research aims to advance the understanding...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $441,178 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at overcoming therapy resistance in pediatric leukemia driven by the NUP98-NSD1 fusion oncoprotein. The key objectives are to: Investigate the cellular and developmental dependency of NUP98-NSD1-mediated leukemic initiation across different hematopoietic stem cell populations. Characterize the...
This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...
The National Cancer Institute (NCI) awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Baylor College of Medicine, a private non-profit university in Houston, Texas. The grant, titled "MYCN Drives a Suppressive Tumor Immune Microenvironment in Neuroblastoma," will fund research to investigate how the MYCN oncogene reprograms T cell metabolism to create an immune-suppressive tumor microenvironment in high-risk neuroblastoma. The goal is to delineate the...